Executive record

Dean L. Schorno

Director at RIGEL PHARMACEUTICALS INC

Follow
More
Challenge a Claim

Alpha ID: alpha:person:dean-l-schornoVersion: public-0As of: 2026-09-28

Not yet claimed8 published Claims4 sources
  • Executive
  • Director

Key Claims

Biography

Appointed CFO in May 2018, Mr. Schorno joined Rigel from 23andMe, Inc. where he had been CFO since 2015, and previously served as CFO of Adaptive Biotechnologies and Genomic Health. He is a certified public accountant with a BS from UC Berkeley and an MS in Taxation from Golden Gate University.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Current · dates not publishedExecutive Vice President and Chief Financial Officer · RIGEL PHARMACEUTICALS INC
  2. 2026 to end not publishedExecutive title: Executive Vice President and Chief Financial Officer · Organization not publishedRIGL DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. RIGL DEF 14A executive officers

    sec filing · Source published: Apr 3, 2026 · Retrieved: May 5, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Executive company: Executive at RIGEL PHARMACEUTICALS INC · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Executive Vice President and Chief Financial Officer · Claim reviewed: May 5, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 5, 2026

  2. Open source

    sec proxy · Source published: Apr 3, 2026 · Retrieved: Sep 2, 2026

    Supports 1 claim
    • Professional Role: Director at RIGEL PHARMACEUTICALS INC · Claim reviewed: Sep 12, 2026

  3. Open source

    sec def 14a · Source published: Apr 3, 2026 · Retrieved: Sep 12, 2026

    Supports 1 claim
    • Professional Role: Executive Vice President and Chief Financial Officer at RIGEL PHARMACEUTICALS INC · Claim reviewed: Sep 12, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of RIGEL PHARMACEUTICALS INC · Claim reviewed: Sep 12, 2026